Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics
GET POWR RATINGS... FREE!
TRVI Stock Price Chart Interactive Chart >
TRVI Price/Volume Stats
| Current price | $1.85 | 52-week high | $4.68 |
| Prev. close | $1.85 | 52-week low | $1.43 |
| Day low | $1.80 | Volume | 45,600 |
| Day high | $1.89 | Avg. volume | 51,131 |
| 50-day MA | $2.23 | Dividend yield | N/A |
| 200-day MA | $2.49 | Market Cap | 111.08M |
Trevi Therapeutics, Inc. (TRVI) Company Bio
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
Latest TRVI News From Around the Web
Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call TranscriptTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. Please note this event is being recorded. Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements […] |
Q4 2022 Trevi Therapeutics Inc Earnings CallQ4 2022 Trevi Therapeutics Inc Earnings Call |
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates. |
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, March 16, 2023, at 4:30 p.m. ET, to provide a corporate update and review the |
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary FibrosisTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF. |
TRVI Price Returns
| 1-mo | -19.21% |
| 3-mo | -4.15% |
| 6-mo | 14.91% |
| 1-year | -2.63% |
| 3-year | -41.08% |
| 5-year | N/A |
| YTD | -4.15% |
| 2022 | 146.74% |
| 2021 | -67.68% |
| 2020 | -35.47% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...